Lorbrexen 100 mg, containing the active ingredient Lorlatinib, is a targeted cancer therapy indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It is specifically recommended for:

• First-line therapy for adult patients with ALK-positive metastatic NSCLC.

• Patients whose disease has progressed on prior ALK inhibitor therapies such as crizotinib, ceritinib, or alectinib.

Lorbrexen is designed to cross the blood-brain barrier, providing effective treatment for both systemic disease and CNS metastases, which are common in ALK-positive NSCLC patients.

Description

Lorbrexen 100 mg is an oral, third-generation ALK and ROS1 tyrosine kinase inhibitor. It works by blocking abnormal signaling pathways that drive cancer cell proliferation and survival. Lorlatinib is engineered to overcome resistance mutations that may develop during treatment with earlier-generation ALK inhibitors, maintaining efficacy in patients with previously treated disease.

Pharmacology

• Mechanism of Action: Lorlatinib selectively inhibits ALK and ROS1 tyrosine kinases, preventing phosphorylation and downstream signaling that promote tumor growth and metastasis.

• CNS Penetration: Designed to penetrate the blood-brain barrier, Lorbrexen effectively treats brain metastases and reduces CNS disease progression.

• Metabolism: Primarily metabolized in the liver via CYP3A4.

• Pharmacokinetics: Oral administration achieves peak plasma concentrations in approximately 1–2 hours. Food does not significantly affect absorption.

Dosage & Administration

• Recommended Dose: 100 mg orally once daily.

• Administration: Swallow capsules whole with water. Take at approximately the same time each day. Do not open, crush, or chew capsules.

• Dose modifications may be necessary for adverse reactions, hepatic impairment, or concomitant use of strong CYP3A inhibitors or inducers.

Drug Interactions

• CYP3A Inhibitors: Strong inhibitors may increase Lorbrexen exposure; avoid co-administration or adjust dose.

• CYP3A Inducers: Strong inducers can reduce effectiveness; co-administration should be avoided.

• Other medications: Caution with drugs that affect lipid metabolism, as Lorbrexen may increase cholesterol and triglyceride levels.

Contraindications

• Known hypersensitivity to Lorlatinib or any excipients.

Side Effects

Common adverse reactions include:

• CNS: Cognitive and mood effects, speech impairment, dizziness, neuropathy.

• Metabolic: Hyperlipidemia (cholesterol and triglycerides), weight gain.

• Other: Fatigue, edema, peripheral neuropathy, diarrhea, constipation, hepatotoxicity.

Serious adverse effects may require temporary dose interruption or reduction. Patients should be closely monitored for cardiac, hepatic, and CNS-related toxicity.

Pregnancy & Lactation

• Pregnancy: Lorbrexen may cause fetal harm; effective contraception is advised during treatment and for at least 1 week after the last dose.

• Lactation: It is unknown if Lorlatinib is present in breast milk; breastfeeding is not recommended during treatment.

Overdose

Limited clinical experience exists. Supportive care and monitoring are recommended in cases of accidental overdose.

Special Populations

• Pediatric Use: Safety and efficacy have not been established in patients under 18 years.

• Geriatric Use: No dose adjustment is typically required, but monitoring for adverse events is advised.

• Hepatic Impairment: Severe impairment may require dose adjustment.

Therapeutic Class

Targeted Cancer Therapy – ALK/ROS1 Inhibitor

Storage Conditions

Store below 30°C in a dry place, protected from light. Keep out of reach of children.